1y return+97.4%S&P 500 +20.9%
3y return+109.6%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2022: $265 against $195 in the S&P 500.2
BML Capital Management, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| ACRSAclaris Therapeutics Inc | $63.3M | 36.2% | −16.0% |
| AVIRAtea Pharmaceuticals Inc | $32.3M | 18.5% | −1.5% |
| ENGNEngene Therapeutics Inc | $11.5M | 6.6% | New |
| KHCKraft Heinz Co | $11.0M | 6.3% | +272.0% |
| OMOutset Med Inc | $10.9M | 6.2% | +32.5% |
| KMXCarmax Inc | $9.1M | 5.2% | +11.3% |
| TLYSTillys Inc | $9.0M | 5.2% | |
| PMVPPmv Pharmaceuticals Inc | $7.1M | 4.1% | |
| TILInstil Bio Inc | $5.0M | 2.8% | |
| TGTTarget Corp | $4.9M | 2.8% | |
| ORMPOramed Pharmaceuticals Inc | $4.2M | 2.4% | −72.6% |
| JANXJanux Therapeutics Inc | $2.4M | 1.4% | |
| PLRXPliant Therapeutics Inc | $1.8M | 1.0% | |
| Connect Biopharma Hldgs LtdCUSIP G23549101 | $1.4M | 0.8% | +40.2% |
| IMAImagenebio Inc | $1.2M | 0.7% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ACRSAclaris Therapeutics Inc | December 31, 2023 | +403.8% | $63.3M |
| ORMPOramed Pharmaceuticals Inc | March 31, 2023 | +120.6% | $4.2M |
| Connect Biopharma Hldgs LtdCUSIP G23549101 | September 30, 2025 | +60.8% | $1.4M |
| TGTTarget Corp | September 30, 2025 | +45.6% | $4.9M |
| KMXCarmax Inc | December 31, 2025 | +36.9% | $9.1M |
| AVIRAtea Pharmaceuticals Inc | June 30, 2023 | +24.3% | $32.3M |
| OMOutset Med Inc | December 31, 2025 | +16.4% | $10.9M |
| JANXJanux Therapeutics Inc | March 31, 2026 | +10.5% | $2.4M |
| KHCKraft Heinz Co | March 31, 2026 | +5.0% | $11.0M |
| TLYSTillys Inc | March 31, 2026 | +3.7% | $9.0M |
Sold off last quarter
- Kezar Life Sciences IncCUSIP 49372L209 was $5.3M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +16.7% | +14.8% |
| March 31, 2026 | +23.1% | −4.6% |
| December 31, 2025 | +24.5% | +2.4% |
| September 30, 2025 | +10.3% | +7.8% |
| June 30, 2025 | +6.2% | +10.5% |
| March 31, 2025 | −17.3% | −4.6% |
| December 31, 2024 | +15.3% | +2.1% |
| September 30, 2024 | +6.8% | +5.4% |
| June 30, 2024 | −2.4% | +4.0% |
| March 31, 2024 | +8.7% | +10.0% |
| December 31, 2023 | −1.7% | +11.2% |
| September 30, 2023 | −5.9% | −3.6% |
| June 30, 2023 | +23.3% | +8.3% |
| March 31, 2023 | +2.7% | +7.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: BML Capital Management, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1616824&type=13F-HR&dateb=&owner=include&count=40CIK 1616824
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1616824/000175496026000696/Filed August 7, 2026 · accession 0001754960-26-000696